

TABLE S1 – OVERVIEW OF THE INCLUDED AUTHORISED MEDICINAL PRODUCTS FOR OUTPATIENT USE (N=407)

| pharmaceutical substance        | ATC 5th level code | therapeutic use              | number of patients (% of population) | patented or off-patent | number of authorised medicinal products |      |            |        | number of marketing authorisation holders (MAHs) |
|---------------------------------|--------------------|------------------------------|--------------------------------------|------------------------|---|------|------------|--------|--|
|                                 |                    |                              |                                      |                        | total                                   | oral | inhalation | rectal |  |
| amoxicillin                     | J01CA04            | bacterial infection          | 815,000 (4.7)                        | off-patent             | 32                                      | 32   |            |        | 9  |
| colecalfiferol                  | A11CC05            | vitamin D deficiency         | 1,005,000 (5.8)                      | off-patent             | 82                                      | 82   |            |        | 24   |
| desloratadine                   | R06AX27            | allergy                      | 740,000 (4.3)                        | off-patent             | 34                                      | 34   |            |        | 17   |
| diclofenac                      | M01AB05            | pain                         | 815,000 (4.7)                        | off-patent             | 29                                      | 21   |            | 8      | 11   |
| levonorgestrel/ethinylestradiol | G03AA07            | contraception                | 1,000,000 (5.7)                      | off-patent             | 21                                      | 21   |            |        | 10   |
| metoprolol                      | C07AB02            | high blood pressure          | 1,010,000 (5.8)                      | off-patent             | 34                                      | 34   |            |        | 10   |
| omeprazole                      | A02BC01            | (prevention of) stomach ache | 1,290,000 (7.4)                      | off-patent             | 85                                      | 85   |            |        | 19   |
| pantoprazole                    | A02BC02            | (prevention of) stomach ache | 1,285,000 (7.4)                      | off-patent             | 33                                      | 33   |            |        | 15   |
| salbutamol                      | R03AC02            | asthma and COPD              | 780,000 (4.5)                        | off-patent             | 21                                      |      | 21         |        | 8  |
| simvastatin                     | C10AA01            | high cholesterol             | 845,000 (4.8)                        | off-patent             | 36                                      | 36   |            |        | 10   |
| Total                           |                    |                              | 6,475,000* (37)                      |                        | 407                                     | 378  | 21         | 8      | 70**   |

\* The total (unique) number of patients is lower than the sum of the number of patients since nearly half of patients used more than one pharmaceutical substance.

\*\*The total number of MAHs is lower than the sum of the MAHs since one MAH can market authorised medicinal products for different substances.